Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease - PubMed (original) (raw)

Review

Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

Ashraf Mikhail et al. BMC Nephrol. 2017.

Abstract

Anaemia is a commonly diagnosed complication among patients suffering with chronic kidney disease. If left untreated, it may affect patient quality of life. There are several causes for anaemia in this patient population. As the kidney function deteriorates, together with medications and dietary restrictions, patients may develop iron deficiency, resulting in reduction of iron supply to the bone marrow (which is the body organ responsible for the production of different blood elements). Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. This substance, which is naturally produced by the kidneys, becomes relatively deficient in patients with chronic kidney disease. Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. In addition, several publications discussed the benefits of each treatment and possible risks associated with long term treatment. The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia, when and how to treat patients with different medications, how to ensure safe prescribing of treatment and how to diagnose and manage complications associated with anaemia and the drugs used for its treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests

All authors made declarations of interest in line with the policy in the Renal Association Clinical Practice Guidelines Development Manual. Further details can be obtained on request from the Renal Association.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

Cited by

References

    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD. - DOI - PMC - PubMed
    1. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int. 2006;70:2058–2065. doi: 10.1038/sj.ki.5001875. - DOI - PubMed
    1. National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on anaemia management in chronic kidney disease. 2015. National Institute for Clinical Excellence. Available on http://www.nice.org.uk/guidance/NG8/evidence. Accessed 15 June 2017.
    1. National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on chronic kidney disease in adults: assessment and management 2014. National Institute for Clinical Excellence. Available on http://www.nice.org.uk/guidance/cg182. Accessed 15 June 2017.
    1. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. NephrolDialTransplant. 2004;19(Suppl 2):ii1–i47. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources